$NUWE News

Last published 6d ago

6d agoNUWENuwellis Submits FDA 510(k) to Expand Aquadex SmartFlow® Indication to Include Pediatric Patients Weighing 5 kg and AboveGlobeNewswireMINNEAPOLIS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it has
1w agoNUWENuwellis to Report Third Quarter 2026 Financial Results on November 12GlobeNewswireMINNEAPOLIS, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it will report financial
2w agoNUWENuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric NephrologyGlobeNewswireMINNEAPOLIS, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the publication of
1mo agoNUWENuwellis to Convene Pediatric Medical & Nursing Advisory Board to Advance Development of Vivian™ Pediatric CRRT SystemGlobeNewswireMINNEAPOLIS, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will
1mo agoNUWENuwellis Reports Strong Aquadex Console Adoption, with 31 Aquadex SmartFlow Consoles Sold Year-to-Date, Meaningfully Expanding Recurring Revenue OpportunityGlobeNewswireMINNEAPOLIS, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced continued
1mo agoNUWENuwellis Strengthens Organization with Appointment of Brian Johnson as Director of Quality and Regulatory AffairsGlobeNewswireMINNEAPOLIS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of
2mo agoNUWENuwellis Advances Financial Efficiency Strategy with Improved Gross MarginsGlobeNewswireMINNEAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlights continued progress
2mo agoNUWENuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility MedicalGlobeNewswireMINNEAPOLIS and MADISON, Wis., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, and Atrility
3mo agoNUWENuwellis' 2nd Quarter 2026 Earnings Conference Call - NUWELLIS INCEarnings Call TranscriptsGood morning, and welcome to New Ellis Earnings Conference Call for the second quarter, ended June 30, 2026. All participants are in a listen-only mode. Should you need assistance, please signal a conferencing specialist
3mo agoNUWENuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross MarginGlobeNewswireRecent capital raise and warrant exercises extend cash runway through second quarter of 2027 Conference call begins at 9:00 a.m. Eastern time today MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc.
3mo agoNUWENuwellis Accelerates Digital Transformation of the Aquadex® Platform with EHR Connectivity and Enhanced User InterfaceGlobeNewswireMINNEAPOLIS, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced a digital
3mo agoNUWENuwellis Strengthens Product Development Organization with Appointment of Dale Brady as Principal R&D EngineerGlobeNewswireMINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of
3mo agoNUWENuwellis Announces Next-Generation Aquadex Platform Strategy to Expand Future Critical Care ApplicationsGlobeNewswireMINNEAPOLIS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced strategic
3mo agoNUWENuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewswireMINNEAPOLIS, July 31, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) ("Nuwellis" or the "Company"), a medical technology company committed to delivering solutions for patients with cardiorenal
3mo agoNUWENuwellis Announces Acceptance by Frontiers in Pediatrics of New Single-Center Retrospective Study Supporting Alternative Anticoagulation Strategy for Aquadex Ultrafiltration TherapyGlobeNewswireMINNEAPOLIS, July 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the acceptance of a new
3mo agoNUWENuwellis Expands Pediatric Footprint with First Aquadex SmartFlow® Installations in WisconsinGlobeNewswireMINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its expansion into
3mo agoNUWENuwellis Announces Preliminary Revenue Results for the Second Quarter 2026 Showing Double Digit GrowthGlobeNewswireCompany expects preliminary revenue year-over-year growth of 14% for second quarter 2026 and 20% for the first half of 2026 as Aquadex Ultrafiltration platform drives continued commercial momentum Nuwellis to report
3mo agoNUWENuwellis Awarded U.S. Patent for Novel Catheter Technology Designed to Enhance Extracorporeal TherapiesGlobeNewswireMINNEAPOLIS, July 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces that the U.S. Patent and
4mo agoNUWENuwellis to Showcase Aquadex Therapy at KidneyBee Summit 2026GlobeNewswireMINNEAPOLIS, July 07, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its participation in the
4mo agoNUWENuwellis Celebrates Five Years of Support of the Pediatric Cardiac Critical Care Consortium (PC⁴)GlobeNewswireMINNEAPOLIS, June 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the five-year anniversary
4mo agoNUWENuwellis Announces Pediatric Expansion in Michigan with First Aquadex SmartFlow® InstallationsGlobeNewswireMINNEAPOLIS, June 25, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its expansion in Michigan
4mo agoNUWEIncoming Nuwellis CEO Mike McCormick Underscores Strategic Priorities for Continued Market Expansion in Pediatric Category and Revenue Generation in Letter to ShareholdersGlobeNewswireMINNEAPOLIS, June 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, reviews the year-to-date and
4mo agoNUWENuwellis Expands Critical Care Education with Aquadex Training at University of Minnesota Critical Care Cardiology Education SummitGlobeNewswireMINNEAPOLIS, June 18, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlighted the clinical utility of
4mo agoNUWENuwellis Appoints Mike McCormick as Chief Executive OfficerGlobeNewswireMINNEAPOLIS, June 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the appointment of Mike
5mo agoNUWENuwellis Expands Collaboration with Major South Carolina Healthcare System to Install New Aquadex SmartFlow® Devices at One of its Children's HospitalsGlobeNewswireMINNEAPOLIS, June 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces an expanded
5mo agoNUWENuwellis Announces Closing of $6.0 Million Registered Public OfferingGlobeNewswireMINNEAPOLIS , June 08, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces the closing of a
5mo agoNUWENuwellis Announces Pricing of $6 Million Public OfferingGlobeNewswireMINNEAPOLIS, June 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces the pricing of a
6mo agoNUWENuwellis Announces Successful Completion of FDA Pre-Submission 510(k) Meeting to Expand Aquadex LabelGlobeNewswireMINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces the successful
6mo agoNUWENuwellis’ 1st Quarter 2026 Earnings Conference CallNUWELLIS INCEarnings Call TranscriptsGood morning and welcome to New Ellis Earnings Conference Call for the first quarter ended March 31st, 2026. All participants will be in a listen-only mode. Should you need assistance, please signal a conference speciali
6mo agoNUWENuwellis, Inc. Announces First Quarter 2026 Financial ResultsGlobeNewswireMINNEAPOLIS, May 12, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for
6mo agoNUWENuwellis, Inc. To Announce First Quarter 2026 Financial Results on May 12, 2026GlobeNewswireMINNEAPOLIS, May 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it will report its
6mo agoNUWENuwellis Highlights Case Study Featuring Precision Ultrafiltration Therapy in Pediatric Cardiorenal Care at ISHLT 2026 Annual MeetingGlobeNewswireMINNEAPOLIS, April 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlights a case study presented
6mo agoNUWENuwellis Announces Receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for Innovative Dual Lumen Midline Catheter TechnologyGlobeNewswireMINNEAPOLIS, April 28, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces that the U.S. Patent and
6mo agoNUWENuwellis to Participate in the AATS 106th Annual Meeting and ERAS Cardiac Spring RetreatGlobeNewswireMINNEAPOLIS, April 23, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it will participate in
6mo agoNUWENuwellis Announces Aquadex Software UpdateGlobeNewswireMINNEAPOLIS, April 21, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on solutions for patients with cardiorenal conditions, today announced a software update to its Aquadex
6mo agoNUWENuwellis Welcomes Back Three Former Team Members to Accelerate Commercial and Clinical MomentumGlobeNewswireMINNEAPOLIS, April 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the return of three
7mo agoNUWENuwellis Engages CORE IR for Public Relations, Shareholder Communications, and Social Media Management ServicesGlobeNewswireMINNEAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it has retained CORE IR,
7mo agoNUWENuwellis Strengthens Commercial Infrastructure with New South Texas TerritoryGlobeNewswireMINNEAPOLIS, April 07, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the creation of a
7mo agoNUWENuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth MilestoneGlobeNewswireMINNEAPOLIS, March 31, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces continued momentum in its
8mo agoNUWENuwellis' 4th Quarter 2025 Earnings Conference CallNUWELLIS INCEarnings Call TranscriptsHello and welcome everyone, joining today's Nouvelles 4th Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the
8mo agoNUWENuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireMINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results
8mo agoNUWENuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal StrategyGlobeNewswireMINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of
8mo agoNUWENuwellis Appoints David A. McDonald and Martin J. Emerson to Board of DirectorsGlobeNewswireMINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of
8mo agoNUWENuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026GlobeNewswireMINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release
9mo agoNUWENuwellis Appoints Carisa Schultz as Chief Financial OfficerGlobeNewswireMINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) a medical technology company focused on advancing precision cardiorenal care, today announced the appointment of Carisa Schultz as Chief
9mo agoNUWENuwellis Announces $5 Million Private Placement and Warrant Inducement Transaction, Priced At-The-MarketGlobeNewswireMINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE) ("Nuwellis" or the "Company"), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today
9mo agoNUWENuwellis Enters into Definitive Agreement to Acquire Rendiatech, Advancing Its Cardiorenal Portfolio StrategyGlobeNewswireMINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced that it has entered
9mo agoNUWENuwellis Announces Changes to Board of DirectorsGlobeNewswireMINNEAPOLIS, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on advancing precision cardiorenal care in critical care settings, today announced the appointment of
10mo agoNUWENuwellis Announces Issuance of New U.S. Patent Supporting Advanced Safety Design for Pediatric Extracorporeal TherapyGlobeNewswireMINNEAPOLIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company advancing precision fluid management technologies across the cardio-renal continuum today announced that the
11mo agoNUWELenox Hill Hospital Study Highlights the Broad Utility of Aquadex in Managing Fluid Overload Across Critical Care SettingsGlobeNewswireMINNEAPOLIS, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, addressing the critical interplay